Advertisement

Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management

  • Jubilee BrownEmail author
  • Michael Frumovitz
Gynecological Cancers (N Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Abstract

Mucinous tumors of the ovary represent a spectrum of neoplastic disorders, including benign mucinous cystadenoma, pseudomyxoma peritonei, mucinous tumors of low malignant potential (borderline), and invasive mucinous ovarian carcinoma. These tumors are related closely to each other and are distinct from other histologic subtypes of epithelial ovarian neoplasms from a clinical, histologic, and molecular standpoint. A continuum appears to be present from benign to borderline to malignant, which is different from other types of epithelial ovarian cancer. Mutational profiles are also distinct, as KRAS mutations are common, but p53 and BRCA mutations are infrequent. These characteristics lead to specific biologic behavior and guide both clinical management and research efforts in patients with mucinous ovarian tumors.

Keywords

Mucinous Mucinous tumor Gynecologic cancers Gynecologic cancer Ovary Carcinoma Tumor Borderline Pseudomyxoma Neoplasm Mucinous ovarian tumors Oncology 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Jubilee Brown and Michael Frumovitz declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Mondal SK, Banyopadhyay R, Nag DR, et al. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital in eastern India. J Cancer Res Ther. 2011;4:433–7.CrossRefGoogle Scholar
  4. 4.
    Koonings PP. Relative frequencies of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921–6.PubMedGoogle Scholar
  5. 5.
    Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol. 2010;29:108–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinoma in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331–4.PubMedCrossRefGoogle Scholar
  10. 10.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophos- phamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.PubMedCrossRefGoogle Scholar
  12. 12.
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106–15.PubMedGoogle Scholar
  13. 13.
    Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–25.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Hart WR, Norris HJ. Borderline and malignant mucinous tumours of the ovary: histologic criteria and clinical behavior. Cancer. 1973;31:1031–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Lack EE, Young RH, Scully RE. Pathology of ovarian neoplasms in childhood and adolescence. Pathol Annu. 1992;27:281–356.PubMedGoogle Scholar
  16. 16.
    Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Tait DL, Miller DS. Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med. 1997;93:89.PubMedGoogle Scholar
  18. 18.
    Chao A, Chao A, Yen YS, Huang CH. Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma. Obstet Gynecol. 2004;104:1180–2.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97:80–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878–82.PubMedCrossRefGoogle Scholar
  24. 24.
    Roger N, Zafrani Y, Uzan C, et al. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol. 2008;15:333–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269–73.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Leblanc E, Querleu D, Narducci F, et al. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Tholander B, Taube A, Lindgren A, et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol. 1990;39:26–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Nolen B, Marrangoni A, Velikokhatnaya L, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009;112:47–54.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108:276–81.PubMedCrossRefGoogle Scholar
  31. 31.
    Fleming GF, Ronnett BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 763–835.Google Scholar
  32. 32.
    NCCN Guidelines - Ovarian Cancer, Version 2.2013, accessed on 10/1/2013.Google Scholar
  33. 33.
    Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118–26.PubMedCrossRefGoogle Scholar
  35. 35.
    Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol. 2012;55:65–74.PubMedCrossRefGoogle Scholar
  36. 36.
    Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘Pseudomyxoma Peritonei’. Am J Surg Pathol. 2000;24:1447–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208:46e1–4.Google Scholar
  38. 38.
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.PubMedCrossRefGoogle Scholar
  39. 39.
    Naik JD, Seligman J, Perren TJ. Mucinous tumors of the ovary. J Clin Pathol. 2012;65:580–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Link Jr CJ, Reed E, Sarosy G, et al. Borderline ovarian tumors. Am J Med. 1996;101:217–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Leys CM, Gasior AC, Hornberger LH, St. Peter SD. Laparoscopic resection of massive ovarian mucinous cystadenoma. J Laparoendosc Adv Surg Tech. 2012;22:307–10.CrossRefGoogle Scholar
  42. 42.
    Eltabbakh GH, Charbonneau AM, Eltabbakh NG. Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol. 2008;108:72–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008;47:1133–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Winter III WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436–41.PubMedCrossRefGoogle Scholar
  46. 46.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32:1835–53.PubMedCrossRefGoogle Scholar
  49. 49.
    Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24:67–72.PubMedCrossRefGoogle Scholar
  50. 50.
    Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36:8–37.PubMedCrossRefGoogle Scholar
  51. 51.
    Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–9.PubMedGoogle Scholar
  52. 52.
    Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378–81.PubMedCrossRefGoogle Scholar
  53. 53.
    Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489–92.PubMedGoogle Scholar
  54. 54.
    Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007;6:491–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Evans DG, Young K, Bulman M, et al. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet. 2008;73:338–45.PubMedCrossRefGoogle Scholar
  56. 56.
    Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat. 2003;21:285–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Marchini S, Mariani P, Chiorino G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008;14:7850–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer. 2006;94:904–13.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37:1042–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Darai E. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol. 2008;33:1239–46.PubMedGoogle Scholar
  61. 61.
    Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Matsuo K, Masato M, Nishimura M, et al. Targeting Src in mucinous ovarian carcinoma. Clin Cancer Res. 2011;17:5367–78.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Gynecologic Oncology and Reproductive SciencesThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations